Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00510510 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: NVA237 100 µg
DRUG: Placebo
DRUG: NVA237 200 µg

Sponsor

Novartis